Planning Underway for Phase 3 Development of Tezepelumab in COPD THOUSAND OAKS, Calif. , April 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE ® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International... Read More

SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis Late-Breaking Phase 3 Study of Otezla in Palmoplantar Pustulosis Achieves Primary and Secondary Endpoints at 16 Weeks THOUSAND OAKS, Calif. , March 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase 3 SPROUT study examining the use of... Read More

THOUSAND OAKS, Calif. , March 6, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024. The dividend will be paid on June 7, 2024 , to all stockholders of record as of the close of business on May 17, 2024 . About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by... Read More

THOUSAND OAKS, Calif. , Feb. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 44 th Annual TD Cowen Health Care Conference at 9:10 a.m. ET on Tuesday , March 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, and Paul Burton , senior vice president and chief medical officer at Amgen, will present at the conference. The webcast will be broadcast over the internet... Read More

THOUSAND OAKS, Calif. , Feb. 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the opening of its manufacturing site in Central Ohio , the newest in its global operations network and the most advanced facility to date. "Our new facility, known as Amgen Ohio, was designed with the latest innovation and technology to deliver safe, reliable medicines for 'every patient, every time,'" said Robert A. Bradway , chairman... Read More

THOUSAND OAKS, Calif. , Feb. 19, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar of growth, and provide insights on its rare disease strategy and opportunities, including marketed products and pipeline. Murdo Gordon , executive vice president of Global Commercial Operations at Amgen, Jay Bradner ,... Read More

THOUSAND OAKS, Calif. , Feb. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 34 th Annual Oppenheimer Healthcare Life Sciences Conference at 12:00 p.m. ET on Wednesday , Feb. 14, 2024. Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, Murdo Gordon , executive vice president of Global Commerical Operations at Amgen, and Susan Sweeney , senior vice... Read More

THOUSAND OAKS, Calif. , Feb. 6, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2023 versus comparable periods in 2022. "2023 was another year of performance and progress for our company," said Robert A. Bradway , chairman and chief executive officer. "Our marketed products are reaching many more patients around the world, and we anticipate more than a dozen... Read More

THOUSAND OAKS, Calif. , Feb. 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024 , after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET . Participating in the call from Amgen will be Robert A. Bradway , chairman and... Read More

REYKJAVIK, Iceland , Jan. 29, 2024 /CNW/ -- Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from Iceland , Denmark, and the USA published a study today in Nature Structural & Molecular Biology titled "Variant in the synaptonemal complex protein SYCE2 associates with pregnancy loss through effects... Read More

THOUSAND OAKS, Calif. , Jan. 3, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Monday, January 8, 2024 . Robert A. Bradway , chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The... Read More

FDA Has Issued New Postmarketing Requirement LUMAKRAS Dosing Confirmed at 960 mg Once-Daily for Patients With KRAS G12C-Mutated NSCLC Under Accelerated Approval THOUSAND OAKS, Calif. , Dec. 26, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company's supplemental New Drug Application seeking full approval of LUMAKRAS ® (sotorasib).... Read More

James Bradner , M.D., Joins as Executive Vice President, Research and Development, and Chief Scientific Officer David M. Reese, M.D., Named Executive Vice President and Chief Technology Officer THOUSAND OAKS, Calif. , Dec. 14, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced two changes to its senior leadership team in the areas of research and development (R&D) and technology, underscoring the advancement of the... Read More

Sponsorship of the Golf Event Continues Following Horizon Acquisition Golfers Shane Lowry , Pádraig Harrington, Séamus Power and Brendan Lawlor Will Become Amgen Golf Ambassadors THOUSAND OAKS, Calif. , Dec. 14, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced it will serve as the title sponsor of the Irish Open starting in 2024, following the acquisition of Horizon Therapeutics plc in October 2023 . Horizon... Read More

Currently There are no Approved Therapeutic Options for Third-Line Treatment of Advanced SCLC 1 If Approved, Tarlatamab Would be the First BiTE ® Therapy for a Major Solid Tumor FDA Target Action Date is June 12, 2024 THOUSAND OAKS, Calif. , Dec. 13, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Company's Biologics... Read More

THOUSAND OAKS, Calif. , Dec. 12, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the first quarter of 2024. This is the 12th consecutive year that Amgen has increased its dividend and comes as the Company continues to invest in innovation and deleverage its balance sheet. The dividend will be paid on March 7, 2024 , to all stockholders of record as... Read More

Multiple Investigator Sponsored Studies Support the Potential of BLINCYTO ® (blinatumomab) Across Acute Lymphoblastic Leukemia Treatment Paradigm New Data Reinforce KYPROLIS ® (carfilzomib) as an Important Treatment Option for Relapsed or Refractory Multiple Myeloma Additional Analyses Support Eculizumab (a biosimilar candidate to SOLIRIS ® ) as a Potential Option in Paroxysmal Nocturnal Hemoglobinuria THOUSAND OAKS, Calif.... Read More

THOUSAND OAKS, Calif. , Nov. 22, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Evercore ISI HealthCONx Conference at 9:10 a.m. EST on Wednesday , Nov. 29, 2023. Peter H. Griffith , executive vice president and chief financial officer at Amgen, and Paul Burton , senior vice president and chief medical officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously... Read More

New Repatha ® (evolocumab) Data Show No Decline in Cognitive Function Associated With Very Low Levels of LDL-C Olpasiran Research Provides Further Insights Into Cardiovascular Risks Associated With Elevated Lp(a) Amgen Provides Updates on Efforts to Advance Bold Ambition of Halving the Number of Heart Attacks and Strokes by 2030 THOUSAND OAKS, Calif. , Nov. 10, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new... Read More

FOREMOST Study Finds Oral Otezla ® (apremilast) Significantly Improved Disease Control vs. Placebo THOUSAND OAKS, Calif. , Nov. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla ® (apremilast) in patients with early oligoarticular psoriatic arthritis. FOREMOST is the first placebo-controlled study designed to specifically assess people with... Read More

First Phase 2 Trial in Sjögren's to Achieve the Primary Endpoint Both in Patients With Severe Symptomatology and Those With Systemic Disease Results From Crossover Period Provide Further Evidence of the Clinical Efficacy and Safety of Dazodalibep in Sjögren's THOUSAND OAKS, Calif. , Nov. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from its Phase 2 study evaluating dazodalibep, an investigational... Read More

THOUSAND OAKS, Calif. , Nov. 2, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data for KRYSTEXXA ® (pegloticase) showing a decrease in blood pressure during treatment of adults living with chronic gout refractory to oral urate-lowering treatment − uncontrolled gout − both with and without chronic kidney disease (CKD). The data will be presented at the American Society of Nephrology Kidney Week, taking place... Read More

Breadth of Research Reflects Amgen's Commitment to Rheumatology Data Include Sjögren's Syndrome, Uncontrolled Gout, Severe Active ANCA-Associated Vasculitis and Psoriatic Arthritis THOUSAND OAKS, Calif. , Nov. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its expanded rheumatology pipeline and portfolio, following the recent acquisition of Horizon... Read More

THOUSAND OAKS, Calif. , Oct. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2023 1 . "We are excited about our pipeline progress and our operating performance in the third quarter," said Robert A. Bradway , chairman and chief executive officer. "With the completion of the Horizon acquisition, Amgen has added rare disease medicines that fit well with our broad... Read More

THOUSAND OAKS, Calif. , Oct. 25, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Tuesday, October 31, 2023 , before the opening of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 5:00 a.m. PT . Participating in the call from Amgen will be Robert A. Bradway , chairman and chief executive... Read More

THOUSAND OAKS, Calif. , Oct. 24, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the fourth quarter of 2023. The dividend will be paid on December 8, 2023 , to all stockholders of record as of the close of business on November 17, 2023 . About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious... Read More

First Global Phase 3 Study in Patients with Chemorefractory KRAS G12C - Mutated Metastatic Colorectal Cancer Results Featured in a Presidential Symposium at ESMO and Simultaneously Published in the New England Journal of Medicine (NEJM) THOUSAND OAKS, Calif. , Oct. 22, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS ® (sotorasib) (960... Read More

Tarlatamab Delivered an Encouraging Objective Response Rate of 40% and Median Overall Survival of 14.3 Months in Patients with Advanced SCLC Late-Breaking Data Presented at ESMO and Published in the New England Journal of Medicine (NEJM) Tarlatamab is an Investigational Delta-Like Ligand 3 (DLL3) Targeting BiTE ® Molecule THOUSAND OAKS, Calif. , Oct. 20, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from... Read More

THOUSAND OAKS, Calif. , Oct. 19, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will host a webcasted call for the investment community at 8:00 a.m. ET on Tuesday , Oct. 24, 2023 following the presentation of new data from Amgen's innovative oncology portfolio including AMG 193 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 and data from tarlatamab,... Read More

Results From Phase 2 DeLLphi-301 Trial Highlight Potential of Tarlatamab, First BiTE in Patients With Previously Treated SCLC Pivotal Phase 3 CodeBreaK 300 Study Data Support LUMAKRAS ® (sotorasib) Plus Vectibix ® (panitumumab) Combination in KRAS G12C-Mutated mCRC Early-Stage Results for AMG 509 (xaluritamig) Illustrate Expanding Potential of Amgen's T-Cell Engagers in mCRPC THOUSAND OAKS, Calif. , Oct. 16, 2023... Read More

Advances Amgen's Mission to Serve Patients With First-in-Class Rare Disease Medicines THOUSAND OAKS, Calif. , Oct. 6, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion . "Today marks an exciting milestone as we welcome Horizon employees to Amgen and... Read More

REYKJAVIK, Iceland , Oct. 4, 2023 /CNW/ -- In a paper released today, deCODE Genetics' scientists shared their findings from a plasma proteomics study performed using affinity-based methods. They analyzed the proteins in the context of diseases and diversity in the sequence of the genome and compared measurements made using... Read More

Network Aims to Advance Collaboration Across Industry and Academia to Accelerate Treatment Development for Patients Inaugural Scientific Summit Prioritized Advancing Translational Research, Pharmacodynamic Readouts and Innovative Biomarker-Driven Programs THOUSAND OAKS, Calif. , Sept. 20, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of Amgen Partners of Choice, a new network that brings together... Read More

THOUSAND OAKS, Calif. , Sept. 11, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 11:40 a.m. BST on Thursday , Sept. 14, 2023. Peter H. Griffith , executive vice president and chief financial officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news... Read More

In Phase 1b Study, Patients Treated in First-Line Demonstrated a Confirmed Objective Response Rate of 65% THOUSAND OAKS, Calif. , Sept. 10, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced exciting data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating LUMAKRAS ® (sotorasib) with carboplatin and pemetrexed in adult patients with KRAS G12C-mutated advanced non-small cell lung cancer... Read More

THOUSAND OAKS, Calif. , Sept. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley Global Healthcare Conference at 8:50 a.m. ET on Tuesday, Sept. 12, 2023 . Robert A. Bradway , chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general... Read More

THOUSAND OAKS, Calif. and DUBLIN , Sept. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's acquisition of Horizon. As a result of the consent order agreement, Amgen and Horizon... Read More

THOUSAND OAKS, Calif. , Aug. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2023 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Wednesday , Sept. 6, 2023. Amgen will also present at the Citi Global Healthcare Conference at 1:00 p.m. ET on Thursday , Sept. 7, 2023. Peter H. Griffith , executive vice president and chief financial officer at Amgen, and Murdo Gordon , executive vice president of global... Read More

Amgen is Changing the Cardiovascular Disease Treatment Landscape With New Research on Innovative Lipid Management New Olpasiran Phase 2 Data Demonstrates Continued Reduction of Lp(a) Nearly a Year After the Last Dose Amgen Convenes First LDL Awareness to Action Implementation Consortium THOUSAND OAKS, Calif. , Aug. 26, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced data from the final analysis of the Phase 2... Read More

THOUSAND OAKS, Calif. , Aug. 21, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data supporting the supplemental New Drug Application (sNDA) for the full approval of LUMAKRAS ® (sotorasib) for adults with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC) at a meeting... Read More

Positive Top-Line Results for Tarlatamab in Small Cell Lung Cancer Positive Top-Line Results for LUMAKRAS ® (Sotorasib) Plus Vectibix ® (Panitumumab) in Metastatic Colorectal Cancer THOUSAND OAKS, Calif. , Aug. 3, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2023. "We had a very strong quarter, serving more patients across all geographies and therapeutic categories and... Read More

THOUSAND OAKS, Calif. , Aug. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the third quarter of 2023. The dividend will be paid on September 8, 2023 , to all stockholders of record as of the close of business on August 18, 2023 . About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses... Read More

THOUSAND OAKS, Calif. , July 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, August 3, 2023 , after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 1:30 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer,... Read More

Conversion From Accelerated to Full Approval Reinforces BLINCYTO as Standard of Care for Patients With Minimal Residual Disease at Baseline After Remission THOUSAND OAKS, Calif. , June 21, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO ® (blinatumomab) for the treatment of adults and... Read More

THOUSAND OAKS, Calif. , June 9, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 44 th Annual Global Healthcare Conference at 2:20 p.m. ET on Wednesday , June 14, 2023. Robert A. Bradway , chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors, and the... Read More

LUMAKRAS ® (sotorasib) Demonstrated Delayed Time to CNS Progression, Longer CNS PFS and Higher Intracranial ORR vs Docetaxel in Post-Hoc Analysis of Phase 3 CodeBreaK 200 Trial LUMAKRAS Shows Improved PFS vs Docetaxel Across Key Co-Alteration Subgroups in the Phase 3 CodeBreaK 200 Study LUMAKRAS Plus Vectibix ® (panitumumab) and FOLFIRI Combination Show ORR of 55% in Previously Treated KRAS G12C-Mutated Metastatic CRC... Read More

New LUMAKRAS ® (sotorasib) Data From First Study Evaluating Intracranial Efficacy of a KRAS G12C Inhibitor Versus Docetaxel in Treated KRAS G12C-Mutated Advanced NSCLC Additional Analyses from DeLLphi-300 Highlight Safety and Clinical Efficacy of Tarlatamab, an Investigational First-in-Class BiTE ® Immunotherapy, in Patients with SCLC With Treated and Stable Brain Metastases Novel Combinations Show Encouraging Safety and... Read More

MOSAIC Study is First to use MRI to Assess Inflammation in Peripheral Joints and Entheses in Psoriatic Arthritis Patients Exploratory Analysis Examines Effects of Otezla on Cardiometabolic Parameters THOUSAND OAKS, Calif. , May 30, 2023 /PRNewswire/ - - Amgen (NASDAQ:AMGN) today announced new research examining the use of Otezla ® (apremilast) in psoriatic arthritis, including the Phase 4 MOSAIC study and an exploratory... Read More

THOUSAND OAKS, Calif. , May 26, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the TD Cowen 4th Annual Oncology Innovation Summit at 11:00 a.m. ET on Wednesday , May 31, 2023. David M. Reese , M.D., executive vice president of Research and Development at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors... Read More

THOUSAND OAKS, Calif. , May 16, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement in response to the U.S. Federal Trade Commission's (FTC) complaint seeking to block the company's proposed acquisition of Horizon Therapeutics plc: "Amgen is disappointed by the FTC's decision and remains committed to completing this acquisition, which will bring significant benefits to patients suffering from very... Read More

Real World Evidence Study Showed use of Prolia Reduced Fracture Risk in Postmenopausal Women With Osteoporosis Versus Alendronate Treatment Longer Duration of Treatment With Prolia Was Associated With Greater Improvements in Fracture Risk Reduction Data is From Real-World Study with Nearly Half a Million Patients Comparing Prolia to Alendronate THOUSAND OAKS, Calif. , May 8, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today... Read More

THOUSAND OAKS, Calif. , May 3, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2023 Bank of America Merrill Lynch Global Healthcare Conference at 11:00 a.m. ET on Tuesday , May 9, 2023. David M. Reese , M.D., executive vice president of Research and Development and Peter H. Griffith , executive vice president and chief financial officer at Amgen will present at the conference. The webcast will be broadcast over... Read More

THOUSAND OAKS, Calif. , April 27, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2023. "We delivered 14% volume growth driven by the breadth of our portfolio and strong demand for our products globally," said Robert A. Bradway , chairman and chief executive officer. "We look forward to closing the acquisition of Horizon Therapeutics and joining forces to reach more... Read More

THOUSAND OAKS, Calif. , April 21, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Thursday, April 27, 2023 , after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 1:30 p.m. PT . Participating in the call from Amgen will be Robert A. Bradway , chairman and chief executive... Read More

Appeals Court Affirms Validity of Patent Expiring in 2028 THOUSAND OAKS, Calif. , April 19, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the District of New Jersey in a patent infringement lawsuit against Sandoz Inc. ("Sandoz") and Zydus Pharmaceuticals ( USA ), Inc. ("Zydus"). Today's decision affirms... Read More

THOUSAND OAKS, Calif. , March 9, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2023 Oppenheimer Healthcare Conference at 2:00 p.m. ET on Monday, March 13, 2023 . Susan Sweeney , senior vice president, Global Marketing, Access and Capabilities at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and... Read More

THOUSAND OAKS, Calif. , March 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the second quarter of 2023. The dividend will be paid on June 8, 2023 , to all stockholders of record as of the close of business on May 18, 2023 . About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by... Read More

THOUSAND OAKS, Calif. , March 3, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2023 TD Cowen Healthcare Conference at 11:10 a.m. ET on Wednesday , March 8, 2023. Murdo Gordon , executive vice president of Global Commercial Operations and Peter H. Griffith , executive vice president and chief financial officer at Amgen will present at the conference. The webcast will be broadcast over the internet... Read More

Combined Data From FOURIER and FOURIER-OLE Studies Show Earlier, Longer Use of Repatha Reduces Total CV Events Analysis From Phase 2 OCEAN(a)-DOSE Study Shows Olpasiran Markedly Reduced Lp(a) Concentration Irrespective of Baseline Level Amgen Convenes First LDL-C Action Summit to Help Improve State of Cardiovascular Disease Care in the U.S. THOUSAND OAKS, Calif. , March 1, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today... Read More

Unique Community-Based Partnership With the Association of Black Cardiologists and Morehouse School of Medicine to Identify Study Sites and Participants Observational Study to Better Understand Associations Between Lp(a) Levels and Atherosclerotic Cardiovascular Disease (ASCVD) in an Underrepresented Patient Population THOUSAND OAKS, Calif. , Feb. 22, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the African... Read More

THOUSAND OAKS, Calif. , Feb. 9, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2023 SVB Securities Global Biopharma Conference at 10:40 a.m. ET on Tuesday, February 14, 2023 . Susan Sweeney , senior vice president, Global Marketing, Access and Capabilities at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media,... Read More

Now Offers Patients the Choice of Administration at Home or in a Doctor's Office THOUSAND OAKS, Calif. , Feb. 2, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE ® (tezepelumab-ekko) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma. 1 First approved by the FDA in December... Read More

THOUSAND OAKS, Calif. , Jan. 31, 2023 /PRNewswire/ -- Amgen ( NASDAQ : AMGN ) posted the full transcript and audio replay of the company's 2022 fourth quarter and full year financial results webcast from earlier today. The transcript, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com ,... Read More

AMGEN ALSO PROVIDES 2023 GUIDANCE EXCLUDING ANY CONTRIBUTION FROM THE ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS THOUSAND OAKS, Calif. , Jan. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year 2022 versus comparable periods in 2021. "We executed effectively in 2022, delivering strong volume growth, advancing numerous first-in-class medicines in our... Read More

Four Years of Real-World Experience in More Than 300,000 Patients and Over 60 Countries 1 THOUSAND OAKS, Calif. , Jan. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira ®* (adalimumab), is now available in the United States . AMJEVITA was the first biosimilar to Humira approved by the U.S. Food and Drug Administration (FDA), in 2016. 2,3 "With today's... Read More

THOUSAND OAKS, Calif. , Jan. 26, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, Jan. 31, 2023 , after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET . Participating in the call from Amgen will be Robert A. Bradway , chairman and chief... Read More

Biotherapeutics Company to Receive lab Space, Mentoring and Other Benefits THOUSAND OAKS, Calif. , Jan. 6, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and BioLabs LA at The Lundquist Institute today announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticket in Southern California . Nammi Therapeutics will receive one year of lab space at BioLabs LA at The Lundquist Institute (TLI) as well as additional... Read More

THOUSAND OAKS, Calif. , Jan. 4, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2023 J.P. Morgan Healthcare Conference at 6:45 p.m. ET on Monday, January 9, 2023 . Robert A. Bradway , chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The... Read More

At 3.5 Years, 83% of Patients on BLINCYTO Plus Chemotherapy Were Alive Versus 65% of Patients on Chemotherapy Alone Trial Design and Conduct Sponsored by the ECOG-ACRIN Cancer Research Group THOUSAND OAKS, Calif. , Dec. 13, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present results from the E1910 randomized Phase 3 trial. This is the first study to... Read More

THOUSAND OAKS, Calif. , Dec. 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the first quarter of 2023. The dividend will be paid on March 8, 2023 , to all stockholders of record as of the close of business on February 15, 2023 . This represents a 10% increase from that paid in each of the previous four quarters. About Amgen Amgen is committed... Read More

THOUSAND OAKS, Calif. , Dec. 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community following the announced acquisition of Horizon Therapeutics at 8:00 a.m. ET on Monday, December 12, 2022 . Robert A. Bradway , chairman and chief executive officer, along with members of the executive team, will participate. The webcast will be broadcast over the internet simultaneously and will be... Read More

THOUSAND OAKS, Calif. , Dec. 12, 2022 /PRNewswire/ -- Summary The board of directors of Horizon Therapeutics plc (the " Company " or " Horizon ") and the board of directors of Amgen Inc. (" Amgen ") are pleased to announce that they have reached agreement on the terms of a cash offer for the Company by Pillartree Limited (" Acquirer Sub "), a newly formed private limited company wholly owned by Amgen, which is unanimously... Read More

AMG 133 is a First-in-Class Investigational Bispecific Molecule That Activates GLP-1R and Inhibits GIPR Phase 1 Results Showed up to 14.5% Reduction in Body Weight at the Highest Dose After 12 Weeks Initiating Phase 2 Study in Early 2023 THOUSAND OAKS, Calif. , Dec. 1, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide... Read More

THOUSAND OAKS, Calif. , Nov. 28, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) at 8:00 a.m. ET on Monday , Dec. 5, 2022. David M. Reese , M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's R&D team, will discuss the Phase 1... Read More

THOUSAND OAKS, Calif. , Nov. 23, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Evercore ISI HealthCONx Conference at 11:20 a.m. ET on Tuesday, November 29, 2022 . David M. Reese , M.D., executive vice president of Research and Development at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the... Read More